A cute ischemic stroke (AIS) management has evolved significantly during the past 20 years, with the development of stroke units and advances in reperfusion therapies. Until recently, reperfusion mainly consisted of intravenous thrombolysis (IVT), which has proven efficacy when administered within 4.5 hours after symptom onset. [1] [2] [3] Mechanical thrombectomy (MT) was limited to basilar artery occlusions and situations in which IVT was contraindicated.
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However, since December 2014, several clinical trials 9-14 have acknowledged the superiority of bridging therapy, which consists of IVT within 4.5 hours followed by MT within 6 hours of symptom onset, over IVT alone in AIS with a large vessel occlusion (LVO) of the anterior circulation. This paradigm shift has proved to be difficult to implement given that fewer than one-third of all stroke centers in the United States (327 of 1148) and in France (37 of 132) are comprehensive stroke centers (CSCs) with on-site interventional neuroradiologic services. 15, 16 In 2011, only 56% of the US population had 60-minute ground access to a CSC, 66% to a primary stroke center (PSC), and 81% to an IVT-capable hospital. Therefore, admitting patients directly to CSCs seems incompatible with the need to start reperfusion therapy as soon as possible. To solve this issue, it has been proposed that patients could receive IVT in a hospital before being transferred to a CSC for MT, a procedure referred to as the drip-and-ship (DS) paradigm, in opposition to direct admission to a CSC, referred to as the mothership (MS). The DS paradigm unavoidably leads to longer process times and could cause a significantly worse prognosis for patients because several meta-analyses 17-23 from clinical trials have found that delaying reperfusion decreases the benefit of MT. Most of the studies on the DS vs MS debate were performed before the generalization of bridging therapy. They focused on IVT or thrombectomy for basilar artery occlusions and often assessed patient outcome at discharge. [24] [25] [26] [27] [28] [29] [30] [31] Three studies 32-34 have more recently been published on the effect of the DS paradigm on patients undergoing bridging therapy, but they have produced conflicting results. The aim of this study was to compare the neurologic outcome and the process times between patients admitted for an AIS with LVO who underwent bridging therapy in a DS vs MS paradigm.
Methods

Study Population
Patients were identified from 2 prospectively gathered and previously described AIS registries (Saint-Antoine Meaning This study found that the 3-month functional independence rates observed in the clinical trials can be reproduced in everyday practice, proving that patients treated under the drip-and-ship paradigm also benefit from bridging therapy.
outcomes (mRS score ≤2) 3 months after the stroke. Secondary outcomes were substantial recanalization and symptomatic intracranial hemorrhage (sICH) rates. Substantial recanalization corresponded to the antegrade reperfusion of more than half (TICI 2B) or all (TICI 3) of the previously occluded target artery ischemic territory. We used the Safe Implementation of Thrombolysis in Stroke-Monitoring (SITS-MOST) study sICH definition: local or remote parenchymal hemorrhage type 2 associated with an increase of 4 points or more in the NIHSS score.
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Brain Imaging Analysis
All patients underwent brain magnetic resonance imaging (MRI) and/or injected computed tomography (CT) during the stroke alert and 24 hours after reperfusion. All were assessed retrospectively by a trained neurologist for the following criteria: diffusionweighted imaging Alberta Stroke Program Early Computed Tomography Score (DWI-ASPECTS) for infarct size (G.G.), axial fluid-attenuated inversion recovery (FLAIR) early vessel sign (G.G.), and occlusion site at time-of-flight magnetic resonance angiography or injected brain CT (I.-P.M.) and after 24 hours for ICH transformation according to the European Cooperative Acute Stroke Study (ECASS) radiologic classification (G.G.).
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Statistical Analysis
Baseline characteristics were compared between patients treated in the DS and MS groups using the 2-tailed, unpaired t test for continuous variables with a normal distribution and the χ 2 test or the Fisher exact test for categorical variables. We then compared 3-month functional independence, substantial recanalization, and sICH rates between the 2 groups by using a multivariate linear model. We included in this final model only variables that were significantly different in the 2 groups (P < .05) in the univariate analysis. We chose not to include process times in the model because they were expected to be longer in the DS group. All statistical analyses were performed using the computer software R-Studio, version 0.99.903 (RStudio). In all analyses, 2-sided P < .05 was considered statistically significant.
Results
Patient Characteristics
During the study period, 497 patients were hospitalized at the DS and MS hospitals for an AIS eligible for reperfusion therapy ( Figure 1 ): 61 were treated with intra-arterial therapy alone (31 in the DS group and 30 in the MS group) because of contraindications to IVT, 266 were treated with IVT alone (144 in the DS group and 122 in the MS group), and 170 were treated with IVT followed by intra-arterial therapy. Among them, 11 patients had a basilar artery occlusion (10 in the DS group and 1 in the MS group) and were excluded, leaving 100 patients in the Median process times were significantly longer in the DS group: onset-to-needle time of 150 minutes (IQR, 120-190 minutes) vs 135 minutes (IQR, 114-155 minutes; P = .02), onset-topuncture times of 248 minutes (IQR, 220-291 minutes) vs 189 minutes (IQR, 163-212 minutes; P < .001), and onset-torecanalization time of 297 minutes (IQR, 255-357 minutes) vs 240 minutes (IQR, 202-285 minutes; P < .001). Needle-topuncture time, an approximation of the transfer delay, was significantly longer in the DS group: 93 minutes (IQR, 79-110 minutes) vs 48 minutes (IQR, 30-67 minutes; P < .001). Four patients in the DS group received IVT after 270 minutes, and MT was started (groin puncture) after 360 minutes in 8 patients (7 in the DS group and 1 in the MS group).
Main and Secondary Outcomes
Three-month mRS scores were available for 149 patients (95 in the DS group and 54 in the MS group), and discharge mRS scores were available for the remaining patients. In the univariate analysis ( In the multivariate analysis, when adjusted on the baseline NIHSS score, the DWI-ASPECTS, and general anesthesia, there was still no significant difference between the 2 groups for the main outcome (P = .82). This was also the case when the onset- 
Subgroup Analyses
We performed a subgroup analysis excluding the patients with an M2 MCA occlusion (15 in the DS group and 5 in the MS group) for 2 reasons. First, we wanted to see whether the difference in terms of the baseline NIHSS score and DWI-ASPECTS was attributable to the more important proportion of M2 MCA occlusions in the DS group, even though it was not statistically significant. Second, we wanted to assess its effect on the main outcome because, in most of the published clinical trials, the proportion of M2 MCA occlusions were lower than in the DS group. The median baseline NIHSS score was still significantly lower in the DS group (16 vs 17 in the MS group; P = .03), but this was not the case for the DWI-ASPECTS. To assess whether early IVT administration had attenuated the effect of increased delays, we compared the main outcome among the patients who underwent MT alone (eTable in the Supplement). There were 54 patients (28 in the DS group and 26 in the MS group) with an occlusion of the anterior circulation. The median onset-to-recanalization times were higher than in the IVT plus MT groups at 301 minutes (IQR, 244-439 minutes) in the DS group vs 286 minutes (IQR, 218-340 minutes) in the MS group, but these times did not differ significantly (P = .10). The 3-month functional independence rate was lower in both groups (10 [35.7%] in the DS group and 7 [26.9%] in the MS group) compared with the IVT plus MT groups but did not significantly differ between them (P = .49). The substantial recanalization rates were slightly but not significantly lower in the DS group (19 [67.8%] in the DS group vs 23 [88.5%] in the MS group; P = .42).
Discussion
Our study found that patients treated using the DS paradigm also benefit from bridging therapy, with no significant difference compared with those treated directly in a CSC and with substantial recanalization and 3-month functional independence rates similar to the results of the previously published clinical trials (Figure 2 and Figure 3) . These results should be interpreted in the context of the 2 debates that have arisen regarding bridging therapy during the past year.
In the first debate, it was questioned whether patients with LVO should be treated as soon as possible with MT, without IVT if it took too long. Indeed, the reperfusion therapy paradigm is that "time is brain" and that the sooner the penumbra is reperfused the better the neurologic outcome will be. for M1 MCA and 13% for ICA occlusions. However, preclinical data suggest that the role of IVT is more complex. In a transient MCA occlusion model, IVT acts on the downstream microvascular thrombosis that starts immediately after the transient occlusion, limiting the infarct extension and yielding better functional results. 41 Moreover, previously published registry studies 42,43 had conflicting results when comparing MT alone with bridging therapy. In the absence of a clinical trial designed to answer this question, bridging therapy remains the only proven treatment for patients presenting with AIS with LVO. Therefore, IVT is the first line of reperfusion treatment and should be administered as soon as possible within 4.5 hours of symptom onset.
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The second debate has focused on the organization required to maximize patient access to bridging therapy, opposing the DS and MS paradigms. With more PSCs than CSCs, DS allows patients to receive IVT as soon as possible at the nearest center and transfer them for MT secondarily. On the other hand, it has been questioned whether the increased process times would result in worse clinical outcomes and higher rates of sICH. Our study found that this supposition is not the case, even though the onset-to-needle time was significantly longer in the DS group (150 vs 135 minutes; P < .001). An important factor in this result was the transfer for MT, which lengthened needle-to-puncture times by only 45 minutes, from 48 minutes in the MS group to 93 minutes in the DS group (P < .001). Indeed, Saver and colleagues 17 recently found in a pooled meta-analysis that the benefit of bridging therapy becomes nonsignificant when the onset-to-puncture time is longer than 438 minutes. Thanks to this limited increase, the median onset-to-puncture time was 248 minutes (Figure 3) , and only 1 patient was over the limit (442 minutes). This finding was equally made possible by the geographic proximity of the 2 centers and the good upstream cooperation. Indeed, Sun and colleagues 44 found that the more often patients are transferred by the same hospital to a CSC, the more often the picture-topuncture time decreases. Similarly, we observed a 21-minute decrease of the needle-to-puncture time during the study period in the DS group. We believe that this outcome was the combined result of a better consideration of the importance of the process times after the publication of the trials and of a learning curve effect at several levels (cooperation between both centers, internal organization, and neuroradiologists' MT expertise). In addition, these results, similar to the ones from the Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intraarterial (EXTEND-IA) trial, were achieved using only the FLAIR early vessel sign, which both groups had in a very high proportion (93.5% in the DS group and 89.3% in the MS group), to assess perfusion and good collateral vascularization. Another way to answer the DS vs MS question could be a prehospital triage that allows transfer of patients with stroke and suspected LVO directly to a CSC. Currently, this scenario remains impossible for several reasons. It is currently impossible to select patients with LVO purely on clinical criteria. Turc and colleagues 45 recently found that using the suggested NIHSS triage cutoffs would result in a false-negative rate of more than 20% and that reducing this rate to 10% would result in sending almost every patient to a CSC. The only way to perform prehospital LVO triage would be to use a specialized CT-equipped mobile stroke unit because it has been tested in Berlin for IVT. 46 However, this process has yet to be tested in a clinical trial and would also require a utility cost analysis given its high cost. Furthermore, even a better prehospital triage would not solve the issue of geographic access, which is particularly important in rural regions, where CSCs are even rarer than in urban areas. Given the available data, it is imperative to start reperfusion therapy with IVT as soon as possible, and delaying IVT to start it directly in a CSC could represent a worse prognosis for patients. Finally, at the current stage, all the CSCs could not admit all the patients requiring bridging therapy. There would have to be a massive development to increase their number and capacity to make it possible, and such a process would take time.
Strengths and Limitations
Our study has several strengths. Both centers had similar practices, and all the patients were treated by the same neuroradiologists. All the imaging criteria were interpreted by the same trained neurologist. Every patient had a baseline NIHSS evaluation, and only 6.3% did not have a 3-month mRS assessment. The study also has limitations. Both centers were in a metropolitan area; thus, the findings may not be relevant to rural hospitals. Its design was retrospective, with a relatively small number of patients. The patients in the MS group had slightly but significantly more severe conditions. This difference could be attributable to an implicit recruitment bias, favored by the presence in the MS of a neurosurgery department and a neurologic intensive care unit.
Conclusions
This study found that patients treated using the DS paradigm also benefit from bridging therapy, with no statistically significant difference compared with those treated directly in a CSC (MS). The delays and 3-month functional independence rates observed in the clinical trials can be reproduced in everyday practice for patients requiring a transfer for MT.
